AI-based Drug Discovery Markets, 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “AI-based Drug Discovery Market: Focus on Deep Learning and Machine Learning, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

The “AI-based Drug Discovery Market: Focus on Machine Learning and Deep Learning, 2020-2030” report features an extensive study of the current market landscape and future potential of the players engaged in offering AI-based services, platforms and tools for the discovery of novel drug candidates. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

One of the key objectives of this report was to estimate the existing market size and the future growth potential within the AI-based drug discovery market. We have developed informed estimates on the financial evolution of the market, over the period 2020-2030.

Amongst other elements, the report features:

• A detailed review of the current market landscape of companies that claim to offer AI-based services, platforms and tools for drug discovery. It includes information on year of establishment, company size (in terms of number of employees), location of headquarters, number of AI-based platforms/tools available, type of AI technology used, drug discovery steps for which the company has expertise involving the use of AI (target identification/validation, lead identification/optimization and ADMET studies), type of drug molecule handled (small molecules, biologics and both), drug development initiatives undertaken by the firm and target therapeutic area.
• An in-depth analysis of the contemporary trends, presented using three schematic representations, including [A] a logo landscape highlighting the distribution of companies based on expertise across drug discovery steps and company size (in terms of number of employees), [B] a world map representation highlighting the distribution of companies based on availability of number of AI-based platforms/tools, and [C] an insightful grid analysis presenting the distribution of companies based on the type of drug molecules handled, expertise across drug discovery steps and geographical presence.
• An analysis of the partnerships that have been inked by stakeholders engaged in the AI-based drug discovery domain, during the period 2009-2020, including research agreements, research and development agreements, technology access/utilization agreements, technology integration agreements, licensing agreements, acquisitions and other relevant types of deals.
• An analysis of the investments made, including award/grant, seed financing, venture capital financing, debt financing and others, in companies that are involved in AI-based drug discovery.
• An elaborate valuation analysis of companies that are involved in the AI-based drug discovery market, based on our proprietary, multi-variable dependent valuation model to estimate the current valuation/net worth of industry players.
• An insightful analysis highlighting the likely cost saving potential associated with the use of AI in the drug discovery sector, based on information gathered from close to 15 countries, taking into consideration various parameters, such as pharmaceutical R&D expenditure, drug discovery expenditure/budget and adoption of AI across various drug discovery steps.
• Elaborate profiles of key players that are engaged in the AI-based drug discovery domain. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective portfolio of platforms/tools, recent developments and an informed future outlook.

The report also provides details on the likely distribution of the current and forecasted opportunity across:

• Geographical regions (North America (the US and Canada), Europe (the UK, France, Germany, Spain, Italy and other European countries), Asia Pacific (China, India, Japan, Australia and South Korea))
• Drug discovery steps (target identification, target validation, hit identification, lead identification and lead optimization)
• Therapeutic areas (oncological disorders, neurological disorders/CNS disorders, infectious diseases, immunological disorders, cardiovascular disorders, metabolic disorders and others)
• End users (pharmaceutical/biotechnology companies, and academic institutes)

Key Questions Answered

• Who are the leading players engaged in the AI-based drug discovery market?
• Which key AI technologies are presently being most commonly adopted by drug discovery focused companies?
• What is the likely valuation/net worth of companies engaged in this domain?
• What is the likely cost saving potential associated with the use of AI in the drug discovery process?
• Which partnership models are most commonly adopted by stakeholders engaged in this industry?
• What is the overall trend of funding and investments within this domain?
• How is the current and future opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. Company Profiles

6. Ai-Based Healthcare Initiatives Of Technology Giants

7. Partnerships And Collaborations

8. Funding And Investment Analysis

9. Company Valuation Analysis

10. Cost Saving Analysis

11. Market Forecast

12. Conclusion

13. Executive Insights

For more information about this report visit https://www.researchandmarkets.com/r/hgwin9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900